Related Experiment Video
Updated: Mar 18, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast
Sara Kangaspeska1,2, Susanne Hultsch3, Alok Jaiswal3
1Institute for Molecular Medicine Finland (FIMM), Biomedicum 2U, Tukholmankatu 8, 00290, Helsinki, Finland. sara.kangaspeska@helsinki.fi.
Background:
The estrogen receptor (ER) inhibitor tamoxifen reduces breast cancer mortality by 31 % and has served as the standard treatment for ER-positive breast cancers for decades. However, 50 % of advanced ER-positive cancers display de novo resistance to tamoxifen, and acquired resistance evolves in 40 % of patients who initially respond. Mechanisms underlying resistance development remain poorly understood and new therapeutic opportunities are urgently needed. Here, we report the generation and characterization of seven tamoxifen-resistant breast cancer cell lines from four parental strains.
Methods:
Using high throughput drug sensitivity and resistance testing (DSRT) with 279 approved and investigational oncology drugs, exome-sequencing and network analysis, we for the first time, systematically determine the drug response profiles specific to tamoxifen resistance.
Results:
We discovered emerging vulnerabilities towards specific drugs, such as ERK1/2-, proteasome- and BCL-family inhibitors as the cells became tamoxifen-resistant. Co-resistance to other drugs such as the survivin inhibitor YM155 and the chemotherapeutic agent paclitaxel also occurred.
Conclusion:
This study indicates that multiple molecular mechanisms dictate endocrine resistance, resulting in unexpected vulnerabilities to initially ineffective drugs, as well as in emerging co-resistances. Thus, combatting drug-resistant tumors will require patient-tailored strategies in order to identify new drug vulnerabilities, and to understand the associated co-resistance patterns.
Insights
Tamoxifen resistance in breast cancer creates new drug vulnerabilities. Researchers identified specific drug targets and co-resistance patterns, highlighting the need for personalized treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tamoxifen is a standard treatment for ER-positive breast cancer, reducing mortality by 31%.
- However, 50% of advanced ER-positive cancers are resistant to tamoxifen initially, and 40% develop acquired resistance.
- Mechanisms of tamoxifen resistance are poorly understood, necessitating new therapeutic approaches.
Purpose of the Study:
- To systematically determine drug response profiles in tamoxifen-resistant breast cancer.
- To identify novel therapeutic vulnerabilities and co-resistance patterns associated with tamoxifen resistance.
Main Methods:
- Generation and characterization of seven tamoxifen-resistant breast cancer cell lines.
- High throughput drug sensitivity and resistance testing (DSRT) using 279 oncology drugs.
- Exome sequencing and network analysis to understand resistance mechanisms.
Main Results:
- Tamoxifen-resistant cells showed vulnerabilities to ERK1/2, proteasome, and BCL-family inhibitors.
- Emerging co-resistance was observed with drugs like YM155 and paclitaxel.
- Multiple molecular mechanisms contribute to endocrine resistance, leading to unexpected drug vulnerabilities.
Conclusions:
- Endocrine resistance in breast cancer involves complex molecular mechanisms.
- Tamoxifen resistance can unveil vulnerabilities to previously ineffective drugs.
- Personalized treatment strategies are crucial to identify drug vulnerabilities and manage co-resistance patterns in drug-resistant tumors.
Related Concept Videos
02:56Treatment Resistant Cancers
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...